Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ervogastat effect on Metformin PK in healthy adults
NCT03593707Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ervogastat in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Metformin (in absence of PF-06865571), Metformin Cmax (in presence of PF-06865571) and 2 more. Started Aug 2018; status: completed.
02
Drugs
ervogastat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03593707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03593707.